Search

Your search keyword '"Wilson, H"' showing total 222 results

Search Constraints

Start Over You searched for: Author "Wilson, H" Remove constraint Author: "Wilson, H" Topic medicine.disease Remove constraint Topic: medicine.disease
222 results on '"Wilson, H"'

Search Results

1. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation

2. Predicted long‐term impact of <scp>COVID</scp> ‐19 pandemic‐related care delays on cancer mortality in Canada

3. The MNK1/2–eIF4E axis supports immune suppression and metastasis in postpartum breast cancer

4. Body mass index and complications following major gastrointestinal surgery

5. Moving towards personalized treatments of immune-related adverse events

6. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer incidence and mortality in Canada

7. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial

8. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors

9. MNK1/Nodal signaling promotes invasive progression of breast ductal carcinoma in situ

10. The 'negative' impact of a subgaleal drain: Post-cranioplasty negative pressure subgaleal drain-induced ascending transtentorial herniation

11. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade

12. Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouse

13. Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-kit

14. Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses

15. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report

16. 797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158

17. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

18. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

19. 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors

20. The pleiotropic effects of the MNK1/2-eIF4E axis support immune suppression and metastasis in a model of postpartum breast cancer

21. High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

22. The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma

23. The MNK1/2-eIF4E axis drives melanoma plasticity, progression, and resistance to immunotherapy

24. A review of cancer immunotherapy: from the past, to the present, to the future

25. Adverse events associated with immune checkpoint inhibitor treatment for cancer

26. An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma

27. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

28. P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma

29. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma

30. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

31. MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression

32. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

33. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

34. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

35. SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study

36. Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study

37. Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients

38. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

39. Abstract S12-01: High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia

40. A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2)

41. FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)

42. A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer

43. Translation of cancer immunotherapy from the bench to the bedside

44. Abstract A53: Phosphorylation of eIF4E promotes phenotype switching and MDSC-mediated immunosuppression in melanoma

45. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils

46. Stepped-wedge randomised trial of laparoscopic ventral mesh rectopexy in adults with chronic constipation: study protocol for a randomized controlled trial

47. Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

48. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

49. The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma

50. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Catalog

Books, media, physical & digital resources